Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSQ-AT Validation in Anemia with Gynecological Malignancies
NCT00121030Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2002
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 2, randomised, open-label trial of darbepoetin alfa in anemia (2 arms), sponsored by Amgen. Primary endpoint: Anemia correction. Started Oct 2002; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00121030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121030.